Idelalisib
- Generic Name
- Idelalisib
- Brand Names
- Zydelig
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18FN7O
- CAS Number
- 870281-82-6
- Unique Ingredient Identifier
- YG57I8T5M0
- Background
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituxi...
- Indication
用于治疗：复发慢性淋巴细胞性白血病(CLL)，与利妥昔单抗联用，在由于其他共患病将考虑对单独利妥昔单抗适当治疗患者。复发滤泡B-细胞非霍奇金淋巴瘤(FL)接受至少2次既往全身治疗患者。复发性小淋巴细胞淋巴瘤(SLL)曾至少接受2次既往全身治疗患者。
- Associated Conditions
- Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed follicular B-cell non-Hodgkin's lymphoma
- Associated Therapies
- -
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
- Conditions
- Interventions
- Locations
- 🇺🇸
Local Institution - 0068, Morgantown, West Virginia, United States
🇺🇸Local Institution - 0121, New York, New York, United States
🇫🇷Local Institution - 0036, Montpellier, Languedoc-Roussillon, France
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05725200
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 6
- Registration Number
- NCT04699461
- Locations
- 🇬🇧
Account University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇪🇸Hospital Universitario La Paz, Madrid, Spain
🇪🇸Hospital Universitario Virgen del Rocío, Sevilla, Spain
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT04666038
- Locations
- 🇨🇦
Princess Margaret Hospital (Ontario), Toronto, Ontario, Canada
🇺🇸Community Health Network, Indianapolis, Indiana, United States
🇨🇳Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 5
- Registration Number
- NCT03890289
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia, Firenze, Italy
🇮🇹AOU Maggiore della Carità di Novara - SCDU Ematologia, Novara, Italy
🇮🇹Azienda sanitaria-universitaria integrata Trieste (ASUITS) - SC Ematologia, Trieste, Italy
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8AnemiaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCastration-Resistant Prostate Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AbirateroneDrug: AfatinibBiological: BevacizumabDrug: BicalutamideProcedure: Biospecimen CollectionDrug: BortezomibDrug: CabazitaxelDrug: CabozantinibDrug: CapecitabineDrug: CarboplatinDrug: CelecoxibDrug: CobimetinibDrug: CopanlisibDrug: DabrafenibDrug: DacomitinibDrug: DarolutamideDrug: DasatinibDrug: DoxorubicinBiological: DurvalumabDrug: EnasidenibDrug: EntrectinibDrug: EnzalutamideDrug: ErlotinibDrug: EverolimusDrug: FluorouracilDrug: IdelalisibDrug: ImatinibBiological: IpilimumabDrug: LenvatinibDrug: LeucovorinDrug: LorlatinibDrug: LosartanDrug: Nab-paclitaxelDrug: NeratinibBiological: NivolumabDrug: OlaparibDrug: OxaliplatinDrug: PalbociclibDrug: PanobinostatBiological: PembrolizumabBiological: PertuzumabDrug: PonatinibOther: Quality-of-Life AssessmentDrug: RegorafenibDrug: RuxolitinibDrug: SirolimusDrug: SorafenibDrug: SunitinibDrug: TrametinibBiological: Trastuzumab EmtansineDrug: TretinoinDrug: VemurafenibDrug: VenetoclaxDrug: VismodegibDrug: Vorinostat
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03878524
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 6
- Registration Number
- NCT03742323
- Locations
- 🇪🇸
Hospital ICO Badalona, Badalona, Spain
🇪🇸Hospital Vall d'Hebrón, Barcelona, Spain
🇪🇸Hospital Clinic de Barcelona, Barcelona, Spain
Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 112
- Registration Number
- NCT03582098
- Locations
- 🇬🇧
NHS Grampian, Aberdeen, United Kingdom
🇬🇧London Northwest University NHS Trust, Eastcote, United Kingdom
🇬🇧Cheltenham General Hospital, Cheltenham, United Kingdom
Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Nordic Lymphoma Group
- Target Recruit Count
- 36
- Registration Number
- NCT03576443
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus C, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
🇸🇪Halmstad County Hospital, Halmstad, Sweden
Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 257
- Registration Number
- NCT03568929
- Locations
- 🇬🇷
University General Hospital of Alexandroupolis, Alexandroupolis, Greece
🇬🇷University General Hospital of Patras, Patra, Greece
🇧🇪Ziekenhuis Netwerk Antwerpen Stuivenberg Hospital, Antwerpen, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.